# Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

> **NCT00471367** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 44 (estimated)

## Conditions studied

- Lymphoma
- NHL
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** AZD4877

## Key facts

- **NCT ID:** NCT00471367
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2008-12
- **Target enrollment:** 44 (ESTIMATED)
- **Why stopped:** Part B of the study was terminated early due to a lack of enrollment.
- **Last updated:** 2009-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471367, "Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00471367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*